CSF3 and myelodysplastic syndrome: When administered with G-CSF, the percentage of low-risk MDS patients who respond to rHuEPO therapy may increase to about 40% (Casadevall et al, 2004; Catenacci & Schiller, 2005; Balleari et al, 2006), particularly in the RARS subtype (Hellstrom-Lindberg et al, 1998, 2003).